NCT05465941
PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Active, Not Recruiting
PHASE2Ages 18+InterventionalTreatmentMayo ClinicInvestigator-initiated
~20 participants
Updated 2026-07-16 on ClinicalTrials.gov
What's tested:BiopsyPegylated SN-38 Conjugate PLX038Computed TomographyBiospecimen Collection
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of confirmed tumor responses
Measured over Up to first 6 cycles of treatment (1 cycle = 21 days)
Conditions
Where it's being run
1 sites across 1 statesMinnesota1
Study leadership
- Andrea E. Wahner Hendrickson, M.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester
- Scott H. Kaufmann, M.D., Ph.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic in Rochester
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Age \>= 18 years NOTE: Because no dosing or adverse event data are currently available on the use of PLX038 in patients \< 18 years of age, children are excluded from this study, but will be eligible for future pediatric trials
Histological confirmed high grade serous ovarian cancer consistent with ovarian, fallopian tube, or primary peritoneal carcinoma (NOTE: Any of these diseases are referred to in this protocol as "ovarian cancer")
Recurrent high grade serous ovarian cancer that was initially platinum sensitive (i.e., had at least one platinum-free interval of at least 6 months before progression) is now platinum resistant
No more than one prior line of therapy for platinum resistant disease. NOTE: Prior poly adenosine diphosphate-ribose polymerase (PARP) inhibitor therapy is allowed
Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
Disease that is amenable to two biopsies
Life expectancy greater \>= 12 weeks
Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
Hemoglobin \>= 8.0 g/dL (obtained =\< 28 days prior to registration)
Absolute neutrophil count (ANC) \>= 1500/mm\^3 (obtained =\< 28 days prior to registration)
Platelet count \>= 100,000/mm\^3 (obtained =\< 28 days prior to registration)
Total bilirubin \>= 1.5 x upper limit of normal (ULN) (obtained =\< 28 days prior to registration)
Alanine aminotransferase (ALT) and aspartate transaminase (AST) =\< 3 x ULN (=\< 5 x ULN for patients with liver involvement) (obtained =\< 28 days prior to registration)
Calculated creatinine clearance \>= 45 ml/min using the Cockcroft-Gault formula (obtained =\< 28 days prior to registration)
Negative pregnancy test done =\< 7 days prior to registration, for persons of childbearing potential only
Provide written informed consent
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study)
Willingness to provide mandatory blood specimens for correlative research
Willingness to provide mandatory tissue specimens for correlative research
Exclusion
Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:
Pregnant persons
Nursing persons
Persons of childbearing potential who are unwilling to employ adequate contraception
Histology other than high grade serous carcinoma
Prior treatment restrictions
Chemotherapy =\< 4 weeks prior to registration
Immunotherapy =\< 4 weeks prior to registration
Radiotherapy =\< 4 weeks prior to registration
Any other investigational therapy =\< 4 weeks prior to registration
History of prior or concurrent malignancy =\< 2 years prior to registration
Exceptions: If natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen
Uncontrolled intercurrent illness including, but not limited to:
Myocardial infarction within 6 months of study entry
New York Heart Association (NYHA) class III or IV heart failure
Uncontrolled dysrhythmias or poorly controlled angina
History of serious ventricular arrhythmia (ventricular tachycardia \[VT\] or ventricular fibrillation \[VF\]) and/or factors that predispose to arrhythmia (e.g., heart failure, hypokalemia, family history of long QT syndrome)
Known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, Exception: Patients should have a clinical risk assessment of cardiac function using the New York Heart Association functional classification. To be eligible for this trial, patients should be class IIB or better Exception: Patients who have received prior doxorubicin (Doxil) are eligible if asymptomatic with QTc =\< 480msec (Fridericia) and NYHA class IIB or better
Known human immunodeficiency virus (HIV) Exception: Patients on effective anti-retroviral therapy with undetectable viral load =\< 6 months prior to registration are eligible for this trial
Known hepatitis
Exception: For patients with evidence of chronic hepatitis B virus infection the HepB viral load must be undetectable on suppressive therapy, if indicated, to be eligible
Exception: Patients with a history of hepatitis C virus infection must have been treated and cured. Patients with HCV infection who are currently on treatment are eligible if they have an undetectable HCV viral load
Receiving any other investigational agent
History of clinically significant gastrointestinal bleeding, colitis, or gastrointestinal perforation
Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
Requirement for anticoagulation treatment that increases international normalized ratio (INR) or activated partial thromboplastin time (APTT) above the normal range (Exceptions: low dose deep vein thrombosis \[DVT\] or line prophylaxis allowed)
Known central nervous system (CNS) disease Exception: Patients with treated brain metastases are eligible if follow-up brain imaging after CNS directed therapy shows no evidence of progression. Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determined that immediate CNS specific treatment is not required and is unlikely to be required during the 1st cycle of therapy
Known Gilbert's syndrome or homozygous for the UGT1A1\*28 variant allele or other relevant alleles with severely reduced UGT1A1 activity
Patients who require treatment with UGT1A1 inhibitors during the planned period of investigational treatment with PLX038
What this trial measures
- Proportion of confirmed tumor responsesUp to first 6 cycles of treatment (1 cycle = 21 days)
A confirmed tumor response is defined to be either a complete response or partial response noted as the objective status on 2 consecutive evaluations at least 4 weeks apart. Confirmed tumor response will be evaluated using the first 6 cycles of treatment. All patients meeting the eligibility criteria who have signed a consent form, have begun treatment, and who have had at least one post-baseline tumor assessment will be evaluable for response. Patients not having met the criteria of having one post-baseline tumor assessment will be considered evaluable if they have discontinued the study due to disease progression.